Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
To investigate the pharmacodynamics, pharmacokinetics and safety of 7-day-repeated doses of
FYU-981 administered orally to male hyperuricemic patients with uric acid-overproduction or
uric acid-underexcretion type.
In addition, to investigate the additive effects of the combination of FYU-981 and
topiroxostat administered orally to male hyperuricemic patients with uric acid-overproduction
type.